Results 191 to 200 of about 15,755 (201)

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

New England Journal of Medicine, 2019
Thierry Facon, Shaji K Kumar, Torben Plesner   +2 more
exaly  

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine, 2016
Athanasios Dimopoulos, Albert Oriol, Hareth Nahi   +2 more
exaly  

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine, 2016
Antonio Palumbo, Katja C Weisel, Ajay K Nooka   +2 more
exaly  

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

New England Journal of Medicine, 2018
María-Victoria Mateos, Athanasios Dimopoulos, Michele Cavo   +2 more
exaly  

Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation

New England Journal of Medicine, 2018
Edwin P Alyea, Jean Marie Connors
exaly  

Benefit with daratumumab maintenance

Nature Reviews Clinical Oncology, 2021
exaly  

Daratumumab in multiple myeloma

Lancet, The, 2016
S Vincent Rajkumar
exaly  

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine
Athanasios Dimopoulos, Mario Boccadoro, Hang Quach   +2 more
exaly  

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

New England Journal of Medicine
Athanasios Dimopoulos, Fredrik Hellem Schjesvold, Vania T M Hungria   +2 more
exaly  

Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma

Nature Reviews Clinical Oncology
Omar Nadeem, Irene M Ghobrial
exaly